|
gptkbp:instanceOf
|
gptkb:drug
gptkb:dopamine_agonist
|
|
gptkbp:approvedBy
|
1997
|
|
gptkbp:ATCCode
|
N04BC05
|
|
gptkbp:availableOn
|
gptkb:tablet
extended-release tablet
|
|
gptkbp:brand
|
Mirapex
Mirapexin
Sifrol
|
|
gptkbp:CASNumber
|
104632-26-0
|
|
gptkbp:chemicalFormula
|
C10H17N3S
|
|
gptkbp:contraindication
|
hypersensitivity to pramipexole
|
|
gptkbp:developedBy
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:drugClass
|
gptkb:antiparkinsonian_agent
dopaminergic agent
|
|
gptkbp:eliminationHalfLife
|
8-12 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:legalStatus
|
prescription only
off-patent
|
|
gptkbp:mechanismOfAction
|
dopamine D2 and D3 receptor agonist
|
|
gptkbp:metabolism
|
minimal hepatic
|
|
gptkbp:molecularWeight
|
211.33 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:orthostatic_hypotension
nausea
drowsiness
compulsive behaviors
hallucinations
|
|
gptkbp:usedFor
|
gptkb:Parkinson's_disease
gptkb:restless_legs_syndrome
|
|
gptkbp:bfsParent
|
gptkb:N04BB
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pramipexole
|